Pelago Bioscience was founded in 2013 with the aim to develop the patented Cellular Thermal Shift Assay (CETSA®) for maximum utility and customer value in drug discovery and diagnostics.

Today, we deliver in situ target engagement studies to accelerate preclinical and clinical drug discovery and development to a world-wide customer base. CETSA® has multiple assay formats that make it a keystone of decision making throughout the drug discovery pipeline.

Unlike other solutions on the market today, its unique approach allows the assessment and quantification of target engagement under physiological conditions – without the need to modify the compound or protein. This provides data that is both actionable and biologically relevant.

Think of CETSA® as snapshots of true target engagement inside the cell, any time you need them.